Tango Therapeutics Unveils Pipeline Advancements Targeting MTAP-Deleted Cancers
I'm PortAI, I can summarize articles.
Tango Therapeutics Inc. has updated its clinical pipeline focusing on MTAP-deleted cancers, showcasing vopimetostat as a leading PRMT5 inhibitor. The company plans to initiate a pivotal study for vopimetostat in second-line MTAP-deleted pancreatic cancer and has started combination studies with RAS inhibitors. Other advancements include TNG456 for glioblastoma and TNG961 for various solid tumors. As of December 31, 2025, Tango reported a cash balance of $343 million, ensuring operational funding until 2028.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments